152 related articles for article (PubMed ID: 33043595)
1. Co-staining of K
Brömmel K; Maskri S; Bulk E; Pethő Z; Rieke M; Budde T; Koch O; Schwab A; Wünsch B
ChemMedChem; 2020 Dec; 15(24):2462-2469. PubMed ID: 33043595
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of Small-Molecule Fluorescent Probes for the In Vitro Imaging of Calcium-Activated Potassium Channel K
Brömmel K; Maskri S; Maisuls I; Konken CP; Rieke M; Pethő Z; Strassert CA; Koch O; Schwab A; Wünsch B
Angew Chem Int Ed Engl; 2020 May; 59(21):8277-8284. PubMed ID: 32097518
[TBL] [Abstract][Full Text] [Related]
3. Imaging of K
Thale I; Maskri S; Grey L; Todesca LM; Budde T; Maisuls I; Strassert CA; Koch O; Schwab A; Wünsch B
ChemMedChem; 2023 Jan; 18(2):e202200551. PubMed ID: 36315933
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the potassium channel K
Staal RGW; Khayrullina T; Zhang H; Davis S; Fallon SM; Cajina M; Nattini ME; Hu A; Zhou H; Poda SB; Zorn S; Chandrasena G; Dale E; Cambpell B; Biilmann Rønn LC; Munro G; Mӧller T
Eur J Pharmacol; 2017 Jan; 795():1-7. PubMed ID: 27876619
[TBL] [Abstract][Full Text] [Related]
5. Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease.
Paka L; Smith DE; Jung D; McCormack S; Zhou P; Duan B; Li JS; Shi J; Hao YJ; Jiang K; Yamin M; Goldberg ID; Narayan P
World J Gastroenterol; 2017 Jun; 23(23):4181-4190. PubMed ID: 28694658
[TBL] [Abstract][Full Text] [Related]
6. KCa 3.1-a microglial target ready for drug repurposing?
Dale E; Staal RG; Eder C; Möller T
Glia; 2016 Oct; 64(10):1733-41. PubMed ID: 27121595
[TBL] [Abstract][Full Text] [Related]
7. Erythrocytes from hereditary xerocytosis patients heterozygous for KCNN4 V282M exhibit increased spontaneous Gardos channel-like activity inhibited by senicapoc.
Rivera A; Vandorpe DH; Shmukler BE; Gallagher DR; Fikry CC; Kuypers FA; Brugnara C; Snyder LM; Alper SL
Am J Hematol; 2017 Jun; 92(6):E108-E110. PubMed ID: 28295477
[No Abstract] [Full Text] [Related]
8. Treatment with senicapoc, a K
Petersen AG; Lind PC; Mogensen S; Jensen AB; Granfeldt A; Simonsen U
Br J Pharmacol; 2022 May; 179(10):2175-2192. PubMed ID: 34623632
[TBL] [Abstract][Full Text] [Related]
9. K
Glaser F; Hundehege P; Bulk E; Todesca LM; Schimmelpfennig S; Nass E; Budde T; Meuth SG; Schwab A
Sci Rep; 2021 Sep; 11(1):18330. PubMed ID: 34526525
[TBL] [Abstract][Full Text] [Related]
10. Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease.
Jin LW; Lucente JD; Nguyen HM; Singh V; Singh L; Chavez M; Bushong T; Wulff H; Maezawa I
Ann Clin Transl Neurol; 2019 Apr; 6(4):723-738. PubMed ID: 31019997
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the K
Organ L; Bacci B; Koumoundouros E; Kimpton WG; Samuel CS; Nowell CJ; Bradding P; Roach KM; Westall G; Jaffar J; Snibson KJ
Am J Respir Cell Mol Biol; 2017 Apr; 56(4):539-550. PubMed ID: 28060543
[TBL] [Abstract][Full Text] [Related]
12. The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity.
Tubman VN; Mejia P; Shmukler BE; Bei AK; Alper SL; Mitchell JR; Brugnara C; Duraisingh MT
Antimicrob Agents Chemother; 2016 Jan; 60(1):613-6. PubMed ID: 26459896
[TBL] [Abstract][Full Text] [Related]
13. A new negative allosteric modulator, AP14145, for the study of small conductance calcium-activated potassium (K
Simó-Vicens R; Kirchhoff JE; Dolce B; Abildgaard L; Speerschneider T; Sørensen US; Grunnet M; Diness JG; Bentzen BH
Br J Pharmacol; 2017 Dec; 174(23):4396-4408. PubMed ID: 28925012
[TBL] [Abstract][Full Text] [Related]
14. Targeting K
Todesca LM; Maskri S; Brömmel K; Thale I; Wünsch B; Koch O; Schwab A
Cell Physiol Biochem; 2021 May; 55(S3):131-144. PubMed ID: 34043300
[TBL] [Abstract][Full Text] [Related]
15. Quantification of the functional expression of the Ca
Blomster LV; Strøbaek D; Hougaard C; Klein J; Pinborg LH; Mikkelsen JD; Christophersen P
Glia; 2016 Dec; 64(12):2065-2078. PubMed ID: 27470924
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of KCa3.1 by depolarisation and 2-aminoethoxydiphenyl borate (2-APB) during Ca²⁺ release activated Ca²⁺ (CRAC) entry in human erythroleukemia (HEL) cells: Implications for the interpretation of 2-APB inhibition of CRAC entry.
Littlechild R; Zaidman N; Khodaverdi D; Mason MJ
Cell Calcium; 2015 Feb; 57(2):76-88. PubMed ID: 25601026
[TBL] [Abstract][Full Text] [Related]
17. Imaging of the calcium activated potassium channel 3.1 (K
Konken CP; Heßling K; Thale I; Schelhaas S; Dabel J; Maskri S; Bulk E; Budde T; Koch O; Schwab A; Schäfers M; Wünsch B
Arch Pharm (Weinheim); 2022 Dec; 355(12):e2200388. PubMed ID: 36161669
[TBL] [Abstract][Full Text] [Related]
18. K
Derseh HB; Dewage SNV; Perera KUE; Pagel CN; Koumoundouros E; Organ L; Snibson KJ
Sci Rep; 2019 Dec; 9(1):19893. PubMed ID: 31882807
[TBL] [Abstract][Full Text] [Related]
19. Functional ion channels in mouse bone marrow mesenchymal stem cells.
Tao R; Lau CP; Tse HF; Li GR
Am J Physiol Cell Physiol; 2007 Nov; 293(5):C1561-7. PubMed ID: 17699636
[TBL] [Abstract][Full Text] [Related]
20. Vertebrate rod photoreceptors express both BK and IK calcium-activated potassium channels, but only BK channels are involved in receptor potential regulation.
Pelucchi B; Grimaldi A; Moriondo A
J Neurosci Res; 2008 Jan; 86(1):194-201. PubMed ID: 17722068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
